B

*click HERE for an explanation of standardised wording to be used by Scottish Boards regarding decisions on medicines since May 2016 Link to Formulary

Medicine	Indication	NHS Board Decision*	DTC Supplement	Date
Baricitinib film-coated tablets (Olumiant®) SMC2572	for the treatment of severe alopecia areata in adult patients.	Not available as not recommended for use in NHS Scotland	194	September 2024
Baricitinib 2mg and 4mg film-coated tablets (Olumiant®) SMC2337	For the treatment of moderate to severe atopic dermatitis in adult patients who are candidates for systemic therapy. SMC restriction: treatment of moderate to severe atopic dermatitis in adult patients who are candidates for systemic therapy who have failed at least one current systemic immunosuppressant due to intolerance, contraindication or inadequate disease control.	Not routinely available as local implementation plans are being developed or the ADTC is waiting for further advice from local clinical experts - decision expected by September 21	185	July 2021
Baricitinib 2mg and 4mg film-coated tablet (Olumiant®) SMC No. (1265/17)	Treatment of moderate to severe active rheumatoid arthritis (RA) in adult patients who have responded inadequately to, or who are intolerant to one or more disease-modifying anti-rheumatic drugs (DMARDs). Baricitinib may be used as monotherapy or in combination with methotrexate	Not routinely available as local clinical experts do not wish to add the medicine to the formulary at this time or there is a local preference for alternative medicine	164	Nov 2017
Beclometasone dipropionate / formoterol fumarate dihydrate / glycopyrronium 172mcg / 5mcg / 9mcg (Trimbow®) SMC2334	Maintenance treatment of asthma, in adults not adequately controlled with a maintenance combination of a long-acting beta2-agonist and high dose of inhaled corticosteroid, and who experienced one or more asthma exacerbations in the previous year Beclometasone dipropionate / formoterol fumarate dihydrate / glycopyrronium (Trimbow®) offers an additional treatment choice of high dose inhaled corticosteroid (ICS), long-acting beta2-agonist (LABA) and long-acting muscarinic antagonist	Available in line with local guidance	190	August 2022

	(LAMA) in a single inhaler. SMC has previously accepted an alternative LAMA as an add-on treatment to ICS and LABA in asthma.			
Beclometasone dipropionate / formoterol fumarate dihydrate / glycopyrronium 87mcg / 5mcg / 9mcg (Trimbow®) SMC2335	Maintenance treatment of asthma, in adults not adequately controlled with a maintenance combination of a long-acting beta2-agonist and medium dose of inhaled corticosteroid, and who experienced one or more asthma exacerbations in the previous year. Beclometasone dipropionate / formoterol fumarate dihydrate / glycopyrronium (Trimbow®) offers an additional treatment choice of medium dose inhaled corticosteroid (ICS), long-acting beta2-agonist (LABA) and long-acting muscarinic antagonist (LAMA) in a single inhaler. SMC has previously accepted an alternative LAMA as an add-on treatment to ICS and LABA in asthma.	Available in line with local guidance for prescribing	184	May 2021
Beclometasone oral (Clipper®) (166/05)	Mild to moderate ulcerative colitis	Not recommended	72	Sept 2007
Beclometasone dipropionate / formoterol fumarate dihydrate / glycopyrronium 87 micrograms / 5 micrograms / 9 micrograms metered dose inhaler (Trimbow®) SMC No (1274/17)	Maintenance treatment in adult patients with moderate to severe chronic obstructive pulmonary disease (COPD) who are not adequately treated by a combination of an inhaled corticosteroid and a long-acting beta2-agonist. SMC restriction: severe COPD (forced expiratory volume in one second less than 50% predicted normal).	Available in line with local guidance	164	Nov 2017
Beclometasone, diproprionate and formoterol MDI (Fostair®) (976/14)	Severe COPD	Formulary	140	Jul/Aug 2014
Beclometasone, formoterol MDI (Fostair®)	Asthma	Formulary - restricted use	97 76	June/Jul 2010 Jan 2008
Beclometasone dipropionate (Clenil Modulite®)	Asthma	Formulary	60	2006
belantamab mafodotin (Blenrep)	As monotherapy for the treatment of multiple myeloma in adult	Not available as not	196 –	Feb 2024

SMC2597	patients, who have received at least four prior therapies and whose disease is refractory to at least one proteasome inhibitor, one immunomodulatory agent, and an anti-CD38 monoclonal antibody, and who have demonstrated disease progression on the last therapy.	recommended for use in NHS Scotland	Awaiting publication	
Belatacept (Nulojix®) (786/12)	Prophylaxis of graft rejection in adults receiving a renal transplant	Not recommended	118	July 2012
Belimumab 200mg solution for injection in pre-filled pen or pre-filled syringe (Benlysta®) SMC2530	Add-on therapy in adult patients with active, autoantibody-positive systemic lupus erythematosus (SLE) with a high degree of disease activity (e.g. Positive anti-dsdna and low complement) despite standard therapy. SMC restriction: in adults with evidence for at least one marker of serological disease activity (low complement, positive anti-dsdna) and a Safety of Estrogens in Lupus Erythematosus National Assessment-Systemic Lupus Erythematosus Disease Activity Index (SELENA-SLEDAI) score ≥10.	Not routinely available as local clinical experts do not wish to add the medicine to the formulary at this time or there is a local preference for alternative medicines.	191	Nov 2022
Belimumab 120mg and 400mg powder for concentrate for solution for infusion (Benlysta®) SMC2477	Add-on therapy in patients aged 5 years and older with active, autoantibody-positive systemic lupus erythematosus (SLE) with a high degree of disease activity (e.g., positive anti-dsdna and low complement) despite standard therapy. SMC restriction: in adults with evidence for at least one marker of serological disease activity (low complement, positive anti-dsdna) and a Safety of Estrogens in Lupus Erythematosus National Assessment-Systemic Lupus Erythematosus Disease Activity Index (SELENA-SLEDAI) score ≥10. Belimumab, in addition to standard therapy, modestly improved disease control in patients with SLE in two phase III studies.	Not routinely available as local clinical experts do not wish to add the medicine to the formulary at this time or there is a local preference for alternative medicines.	191	Nov 2022
belimumab 120mg, 400mg	In combination with background immunosuppressive therapies	Not available as not	189	May 2022

powder for concentrate for solution for infusion and 200mg solution for injection in pre-filled pen (Benlysta®) SMC2483	for the treatment of adult patients with active lupus nephritis.	recommended for use in NHS Scotland		
Belimumab, 120mg and 400mg powder for concentrate for solution for infusion (Benlysta®) SMC No. (775/12)	Add-on therapy in adult patients with active, autoantibody-positive systemic lupus erythematosus (SLE) with a high degree of disease activity (e.g. positive anti-dsDNA and low complement) despite standard therapy Restriction: patients with evidence of serological disease activity (i.e. positive anti-dsDNA and low complement) and a Safety of Estrogens in Lupus Erythematosus National Assessment-Systemic Lupus Erythematosus Disease Activity Index (SELENA-SLEDAI) score ≥10.	Not routinely available as local clinical experts do not wish to add the medicine to the formulary at this time or there is a local preference for alternative medicines	117 162	May/June 2012 Aug 2017
Belumosudil film-coated tablet (Rezurock®) SMC2583	Treatment of patients aged 12 years and older with chronic graft-versus-host disease (chronic GvHD) who have received at least two prior lines of systemic therapy.	Available in line with national guidance	194	September 2023
Belzutifan film-coated tablets (Welireg®) SMC2587	treatment of adult patients with von Hippel-Lindau (VHL) disease who require therapy for VHL associated renal cell carcinoma (RCC), central nervous system (CNS) hemangioblastomas, or pancreatic neuroendocrine tumours (pNET), and for whom localised procedures are unsuitable or undesirable.	Not routinely available as local clinical experts do not wish to add the medicine to the formulary at this time or there is a local preference for alternative medicines.	195	December 2023
Bemiparin (Zibor®)	Prevention of thromboembolic disease – general surgery	Not recommended	54	2005
Bemiparin (Zibor®) (204/05)	Prevention of thromboembolic disease – orthopaedic surgery	Non-formulary	94 71 54	Dec 09/Jan 10 July 2007 2005
Bemiparin (Zibor®)	Prevention of clotting in extracorporeal circuit during haemodialysis	Not recommended	54	2005

Bemiparin (Zibor®) (206/05)	Treatment of venous thromboembolism	Not recommended	71 54	July 2007 2005
Bempedoic acid / ezetimibe film-coated tablets (Nustendi®) SMC2741	In adults with established or at high risk for atherosclerotic cardiovascular disease to reduce cardiovascular risk by lowering LDL-C levels, as an adjunct to correction of other risk factors: • in patients on a maximum tolerated dose of a statin and not adequately controlled with additional ezetimibe treatment or, • in patients who are either statin-intolerant, or for whom a statin is contraindicated, and not adequately controlled with ezetimibe treatment or, • in patients already being treated with the combination of bempedoic acid and ezetimibe as separate tablets.	Not available as not recommended for use in NHS Scotland		
Bempedoic acid film-coated tablets (Nilemdo®) SMC2740	In adults with established or at high risk for atherosclerotic cardiovascular disease to reduce cardiovascular risk by lowering LDL-C levels, as an adjunct to correction of other risk factors: • in patients on a maximum tolerated dose of a statin with or without ezetimibe or, • alone or in combination with ezetimibe in patients who are statin-intolerant, or for whom a statin is contraindicated	Not available as not recommended for use in NHS Scotland		
bempedoic acid / ezetimibe 180mg / 10mg film-coated tablets (Nustendi®)SMC2406	in adults with primary hypercholesterolaemia (heterozygous familial and non-familial) or mixed dyslipidaemia, as an adjunct to diet: • in combination with a statin in patients unable to reach LDL-C goals with the maximum tolerated dose of a statin in addition to ezetimibe, • alone in patients who are either statin-intolerant or for whom a statin is contraindicated, and are unable to reach LDL-C goals with ezetimibe alone • in patients already being treated with the combination of bempedoic acid and ezetimibe as separate tablets with or	Available in line with local guidance for prescribing	187	Dec 2021

	without statin. SMC restriction: for use in patients who are: • statin intolerant or for whom a statin is contra-indicated and • where ezetimibe alone does not appropriately control LDL-C and • where proprotein convertase subtilisin/ kexin type 9 (PCSK9) inhibitors are not appropriate SMC has previously accepted bempedoic acid for restricted use in combination with ezetimibe for this indication. Nustendi® (bempedoic acid / ezetimibe) provides a single tablet alternative to bempedoic acid plus ezetimibe.			
Bempedoic acid 180mg film-coated tablets (Nilemdo®) SMC2363	In adults with primary hypercholesterolaemia (heterozygous familial and non-familial) or mixed dyslipidaemia, as an adjunct to diet: • In combination with a statin, or a statin with other lipid-lowering therapies in patients unable to reach low-density lipoprotein cholesterol (LDL-C) goals with the maximum tolerated dose of a statin or • Alone or in combination with other lipid-lowering therapies in patients who are statin-intolerant, or for whom a statin is contra-indicated. SMC restriction: for use in combination with ezetimibe in patients who are: • statin intolerant or for whom a statin is contra-indicated and • where ezetimibe alone does not appropriately control LDL-C and • where proprotein convertase subtilisin/ kexin type 9 (PCSK9) inhibitors are not appropriate	Available in line with national guidance	186	Sept 2021
Bempedoic acid 180mg film-coated tablets (Nilemdo®) SMC2292	In adults with primary hypercholesterolaemia (heterozygous familial and non-familial) or mixed dyslipidaemia, as an adjunct to diet: • In combination with a statin, or a statin with other lipid-	Not available as not recommended for use in NHS Scotland	182	January 2021

	lowering therapies in patients unable to reach LDL-C goals with the maximum tolerated dose of a statin or • Alone or in combination with other lipid-lowering therapies in patients who are statin-intolerant, or for whom a statin is contra-indicated.			
Bendamustine (Levact®) (694/11)	CLL	Non-formulary - pending protocol update	118 105	July 2012 April/May 2011
Bendamustine (Levact®) (700/11)	Multiple myeloma	Not recommended	105	April/May 2011
Bendamustine (Levact®) (701/11)	Non-Hodgkin's lymphomas	Not recommended	105	April/May 2011
Benralizumab 30mg solution for injection in pre filled syringe (Fasenra®) SMC2155	As an add-on maintenance treatment in adult patients with severe eosinophilic asthma inadequately controlled despite high-dose inhaled corticosteroids plus long-acting β-agonists. SMC restriction: patients with blood eosinophils ≥150 cells/microlitre, and either ≥4 prior asthma exacerbations needing systemic corticosteroids in the previous 12 months or treatment with continuous oral corticosteroids over the previous 6 months.	Not routinely available as local clinical experts do not wish to add the medicine to the formulary at this time or there is a local preference for alternative medicines.	175 176	Aug 2019 Oct 2019
berotralstat 150mg hard capsules (Orladeyo®) SMC2405	Routine prevention of recurrent attacks of hereditary angioedema (HAE) in adult and adolescent patients aged 12 years and older. SMC restriction: patients who experience ≥ two clinically significant attacks per month.	Available in line with national guidance	188	April 2022
Betaine (Cystadane®) (407/07)	Homocystinuria	HOSPITAL ONLY - restricted use	99 87 73	Aug/Sept 2010 March 2009 Oct 2007
Betamethasone valerate (Betesil®) (622/10)	Inflammatory skin disorders	Not recommended	99	Aug/Sept 2010

bevacizumab gamma (Lytenava®) SMC2744	in adults for treatment of neovascular (wet) age-related macular degeneration (nAMD). Bevacizumab gamma offers an additional treatment choice in the therapeutic class of vascular endothelial growth factor inhibitors.	Not routinely available as local clinical experts do not wish to add the medicine to the formulary at this time or there is a local preference for alternative medicines.		
Bevacizumab 25mg/mL concentrate for solution for infusion (Avastin®) SMC No. (1275/17)	In combination with carboplatin and paclitaxel for the treatment of adult patients with first recurrence of platinum-sensitive epithelial ovarian, fallopian tube or primary peritoneal cancer who have not received prior therapy with bevacizumab or other VEGF inhibitors or VEGF receptor–targeted agents.	Not available as not recommended for use in NHS Scotland	164	Nov 2017
Bevacizumab 25mg/mL concentrate for solution for infusion (Avastin®) SMC (1190/16)	In combination with erlotinib for first-line treatment of adult patients with unresectable advanced, metastatic or recurrent non-squamous non-small cell lung cancer with Epidermal Growth Factor Receptor (EGFR) activating mutations.	Not available as not recommended for use in NHS Scotland.	157	Nov 2016
Bevacizumab 25mg/mL concentrate for solution for infusion (Avastin®) SMC 1135/16	In combination with paclitaxel and cisplatin or, alternatively, paclitaxel and topotecan in patients who cannot receive platinum therapy, for treatment of adult patients with persistent, recurrent, or metastatic carcinoma of the cervix. SMC Restriction: for use with cisplatin and aclitaxel	Available in line with National guidance	155	June 2016
Bevacizumab (Avastin®) (1063/15)	In combination with paclitaxel, topotecan, or pegylated liposomal doxorubicin for the treatment of adult patients with platinum-resistant recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer whoreceived no more than two prior chemotherapy regimens and who have not received prior therapy with bevacizumab or other vascular endothelial growth factor (VEGF) inhibitors or VEGF receptor-targeted agents.	Available in line with national guidance	151 157	Sep/Oct 2015 Nov 2016

	SMC Restriction: to use in combination with paclitaxel.			
Bevacizumab (Avastin®) (853/13)	First recurrence of platinum-sensitive epithelian ovarian, fallopian tube or primary peritoneal cancer	Not recommended	126	Apr 2013
Bevacizumab (Avastin®) (806/12)	In combination with carboplatin and paclitaxel, for the front-line treatment of advanced (International Federation of Gynaecology and Obstetrics (FIGO) stages IIIB, IIIC and IV) epithelial ovarian, fallopian tube, or primary peritoneal cancer. SMC restriction: In patients with FIGO stage IV disease.	Formulary Hospital use only (Oncology)	145 121 152 153	Feb 2015 Nov 2012 Nov/Dec 2015 Jan/Feb 2016
Bevacizumab (Avastin®) (459/08)	Advanced and/or metastatic renal cell cancer	Not recommended	81	July 2008
Bevacizumab (Avastin®) (425/07)	Advanced non-small cell lung cancer (NSCLC)	Not recommended	75	Dec 2007
Bevacizumab (Avastin®) (778/12)	Metastatic breast cancer	Not recommended	117 71	May/June 2012 July 2007
Bevacizumab (Avastin®) (469/08)	Metastatic colorectal cancer	Not recommended	81 80 59 55	July 2008 June 2008 2006
Bexarotene capsules (Targretin®) (14/02)	Skin manifestations of advanced stage CTCL	HOSPITAL ONLY - restricted use	22	2002
Bezlotoxumab 25mg/mL concentrate for solution for infusion (Zinplava®) SMC No 1293/17	Prevention of recurrence of Clostridium difficile infection (CDI) in adults at high risk for recurrence of CDI.	Not available as not recommended for use in NHS Scotland	166	Feb 2018
Bictegravir / emtricitabine /	Treatment of human immunodeficiency virus-1 (HIV-1) infection	Not available as not		

tenofovir alafenamide 30 mg / 120 mg / 15 mg film-coated tablet (Biktarvy®) SMC2760	in paediatric patients at least 2 years of age and weighing at least 14 kg to less than 25 kg without present or past evidence of viral resistance to the integrase inhibitor class, emtricitabine or tenofovir.	recommended for use in NHS Scotland		
Bictegravir 50mg / emtricitabine 200mg / tenofovir alafenamide 25mg film-coated tablet (Biktarvy®) SMC2093	Treatment of adults infected with human immunodeficiency virus 1 (HIV-1) without present or past evidence of viral resistance to the integrase inhibitor class, emtricitabine or tenofovir. Bictegravir / emtricitabine / tenofovir alafenamide was non-inferior for control of HIV-1 infection compared with anti-retroviral regimens comprising an integrase inhibitor plus backbone of dual nucleos(t)ide reverse transcriptase inhibitors (NRTIs) in treatment-naïve adults. Bictegravir / emtricitabine / tenofovir alafenamide was non-inferior to anti-retroviral regimens containing a dual NRTI backbone plus an integrase inhibitor or a protease inhibitor in maintaining virological suppression in virologically suppressed adults	Available in line with national guidance	171	Oct 2018
Bilastine (Ilaxten®) (730/11)	Allergic rhinoconjunctivitis and urticaria	Not recommended	109	Sept 2011
Bimatoprost (Lumigan UD®) (839/13)	Chronic open-angle glaucoma and ocular hypertension in adults	Non-formulary - alternatives preferred	126	Apr 2013
Bimatoprost (Ganfort® Unit Dose Preservative Free) (906/13)	For the reduction of intraocular pressure (IOP) in adult patients with open-angle glaucoma or ocular hypertension who are insufficiently responsive to topical beta-blockers or prostaglandin analogues.	GPs under direction of Ophthalmology	132 131	Nov/Dec 2013 Oct/Nov 2013
Bimatoprost/timolol (Ganfort®)	Glaucoma/ocular hypertension	Non-formulary	62	2006
bimekizumab solution for injection in pre-filled syringe and pre-filled pen (Bimzelx®) SMC2698	for the treatment of active moderate to severe hidradenitis suppurativa (HS) (acne inversa) in adults with an inadequate response to conventional systemic HS therapy. SMC restriction: for use in adult patients with active moderate			

	to severe HS for whom adalimumab is contraindicated or otherwise unsuitable, including those who have failed to respond or have lost response to prior adalimumab treatment.			
bimekizumab 160mg solution for injection in pre-filled syringe/ prefilled pen (Bimzelx) SMC2616	"axial spondyloarthritis	Not routinely available as local clinical experts do not wish to add the medicine to the formulary at this time or there is a local preference for alternative medicines.	196 – Awaiting publication	February 2024
bimekizumab solution for injection in pre-filled syringe and pre-filled pen (Bimzelx®) SMC2605	Alone or in combination with methotrexate, for the treatment of active psoriatic arthritis in adults who have had an inadequate response or who have been intolerant to one or more disease-modifying antirheumatic drugs (DMARDs).	Not routinely available as local clinical experts do not wish to add the medicine to the formulary at this time or there is a local preference for alternative medicines.	195	December 2023
Bimekizumab 160mg solution for injection in pre-filled syringe and pre-filled pen (Bimzelx®) SMC2410	Treatment of moderate to severe plaque psoriasis in adults who are candidates for systemic therapy. SMC restriction: for patients who have failed to respond to standard systemic therapies (including ciclosporin, methotrexate and phototherapy), are intolerant to, or have a contra-indication to these treatments.	Available in line with local guidance	188	April 2022
Biphasic insulin Aspart (Novomix® 30)	Diabetes mellitus		27	2002
Birch bark extract gel (Filsuvez®) SMC2651	Treatment of partial thickness wounds associated with dystrophic and junctional epidermolysis bullosa (EB) in patients 6 months and older.	Available in line with national guidance	198 not yet published	
Bismuth subcitrate potassium/ metronidazole/ tetracycline hydrochloride hard capsules (Pylera®) SMC2701	In combination with omeprazole, for the eradication of Helicobacter pylori and prevention of relapse of peptic ulcers in patients with active or a history of H. pylori associated ulcers SMC restriction: restricted to use in accordance with clinical	Not routinely available as local implementation plans are being developed by Antimicrobial Management		

	guidelines for the eradication of H. pylori	Group - decision expected by December 2024.		
Bivalirudin (Angiox®) (516/08)	Acute coronary syndromes planned for urgent or early intervention		85	Dec 2008
Bivalirudin (Angiox®) (638/10)	Anticoagulant in PCI	Not routinely recommended in Tayside	100 99 49	Oct/Nov 2010 Aug/Sept 2010 2005
blinatumomab 38.5 micrograms powder for concentrate and solution for solution for infusion (Blincyto®) SMC2459	As monotherapy for the treatment of adults with CD19 positive relapsed or refractory B-precursor acute lymphoblastic leukaemia (ALL). Patients with Philadelphia chromosome positive B-precursor ALL should have failed treatment with at least 2 tyrosine kinase inhibitors (TKIs) and have no alternative treatment options.	Not available as not recommended for use in NHS Scotland	188	April 2022
Blinatumomab 38.5 micrograms powder for concentrate and solution for solution for infusion (Blincyto®) - SMC 2234	As monotherapy for the treatment of adults with Philadelphia chromosome negative, CD19 positive, B-precursor acute lymphoblastic leukaemia (ALL) in first or second complete remission with minimal residual disease (MRD) greater than or equal to 0.1%. SMC restriction: to patients who are in first complete remission with minimal residual disease (MRD) greater than or equal to 0.1%.	Not routinely available as local clinical experts do not wish to add the medicine to the formulary at this time or there is a local preference for alternative medicines	180	Sept 2020
Blinatumomab 38.5 micrograms powder for concentrate and solution for infusion (Blincyto®) SMC2148	As monotherapy for the treatment of paediatric patients aged 1 year or older with Philadelphia chromosome negative CD19 positive B-cell precursor acute lymphoblastic leukaemia which is refractory or in relapse after receiving at least two prior therapies or in relapse after receiving prior allogeneic hematopoietic stem cell transplantation	Available from a specialist centre in another NHS Board	174	May 2019
Blinatumomab (Blincyto®)	The treatment of adults with Philadelphia chromosome negative relapsed or refractory B-precursor acute lymphoblastic	Not routinely available as local clinical experts do not wish to	156	Sep 2016

1145/16	leukaemia (ALL).	add the medicine to the formulary at this time or there is a local preference for alternative medicines		
Boceprevir (Victrelis®) (722/11)	Chronic hepatitis C (HCV) - treatment experienced	HOSPITAL ONLY (Hepatitis Clinic)	111	Nov 2011
Boceprevir (Victrelis®) (723/11)	Chronic hepatitis C (HCV) - treatment naive	HOSPITAL ONLY (Hepatitis Clinic)	111	Nov 2011
Bortezomib (Velcade®) (1075/15)	In combination with rituximab, cyclophosphamide, doxorubicin and prednisone for the treatment of adult patients with previously untreated mantle cell lymphoma who are unsuitable for haematopoietic stem cell transplantation.	Non formulary - pending local decision	151	Sep/Oct 2015
Bortezomib (Velcade®) (927/13)	Multiple myeloma	HOSPITAL ONLY (Haematology/Oncology)	134	Jan/Feb 2014
Bortezomib (Velcade®) (822/12)	Multiple myeloma	HOSPITAL ONLY (Haematology)	123	Jan 2013
Bortezomib (Velcade®) (126/04) & (302/06)	Multiple myeloma	HOSPITAL ONLY (Haematology)	108 Protocol 93 72 61 45	Aug 2011 Oct/Nov 2009 Sep 2007 2006 2004
Bosentan (Tracleer®) (523/08)	Class II pulmonary arterial hypertension	Not recommended	84	Nov 2008
Bosentan (Tracleer®) (458/08)	To reduce number of new digital ulcers in patients with systemic sclerosis and ongoing digital ulcer disease	Not recommended	80	Jun 2008
Bosentan (Tracleer®)	Grade III Pulmonary arterial hypertension		25	2003
Bosutinib 100mg, 400mg and 500mg film-coated tablets	Treatment of adult patients with newly diagnosed chronic phase Philadelphia chromosome-positive chronic	Not available as not recommended for use in NHS	170	Sep 2018

(Bosulif ®) SMC No 2109	myelogenous leukaemia.	Scotland		
Bosutinib (Bosulif®) (910/13)	Adult patients with chronic phase, accelerted phase and blast phase Ph + CML previously treated with one or more tyrosine kinase inhibitor(s) and for whom imatinib, nilotinib and dasatinib are not considered appropriate treatment options.	Non-formulary - lack of clinician demand	146 132	Feb 2015 Nov/Dec 2013
Botulinum toxin type A (Botox®) (931/13)	Management of bladder dysfunctions in adult patients	HOSPITAL ONLY - Urology	140 133	Jul/Aug 2014 Dec 13/Jan 14
Botulinum toxin type A (Botox®) (986/14)	Focal lower limb spasticity	Not recommended	140	Jul/Aug 2014
Botulinum toxin Type A (Xeomin®) (731/11)	Post-stroke spasticity of the upper limb	Non-formulary - alternatives preferred	116 115 111	Apr/May 2012 Mar/Apr 2012 Nov 2011
Botulinum toxin Type A (Bocouture®)	Moderate to severe glabellar lines	Not recommended	104	Mar 2011
Botulinum toxin Type A (Azzalure®) (679/11)	Appearance of moderate to severe glabellar lines	Not recommended	102	Jan/Feb 2011
Botulinum toxin Type A (Vistabel®) (680/11)	Appearance of moderate to severe glabellar lines	Not recommended	102	Jan/Feb 2011
Botulinum toxin type A (Botox®) (916/13)	Management of urinary incontinence in adult patients.	HOSPITAL ONLY - Urology	131	Oct/Nov 2013
Botulinum toxin A, 50 Allergan units, 100 Allergan units, 200 Allergan units, powder for solution for injection (Botox®)	Prophylaxis of headaches in adults with chronic migraine (headaches on at least 15 days per month of which at least 8 days are with migraine). SMC Restriction: use in adults with chronic migraine whose condition has failed to respond to	Available in line with local guidance for prescribing	127 105 160	May 2013 Apr/May 2011 Apr 2017 Aug 2017

SMC No. 692/11	≥3 prior oral prophylactic treatments, where medication overuse has been appropriately managed.	Formulary - Hospital Only	162	
Botulinum Type A neurotoxin complex (Botox®) (80/03)	Post stroke hand & wrist spasticity	HOSPITAL ONLY - Centre for Brain Injury Rehabilitation	104 39 33	Mar 2011 2004 2003
Brentuximab vedotin 50mg powder for concentrate for solution for infusion (Adcetris®) SMC2310	Indication under review: in combination with cyclophosphamide, doxorubicin and prednisone (CHP) for adult patients with previously untreated systemic anaplastic large cell lymphoma (sALCL). In a phase III study, brentuximab vedotin in combination with CHP was associated with a significant improvement in progression-free survival compared with CHOP (cyclophosphamide, doxorubicin, vincristine, prednisone) chemotherapy.	Available in line with local guidance for prescribing	183	March 2021
Brentuximab vedotin 50mg powder for concentrate for solution for infusion (Adcetris®) SMC 2229	The treatment of adult patients with CD30+ cutaneous T-cell lymphoma (CTCL) after at least one prior systemic therapy	Available in line with local guidance for prescribing	179	Apr 2020
Brentuximab vedotin 50mg powder for concentrate for solution for infusion (Adcetris®) SMC2202	Treatment of adult patients with previously untreated CD30+ Stage IV Hodgkin lymphoma in combination with doxorubicin, vinblastine and dacarbazine.	Not available as not recommended for use in NHS Scotland.	175	Aug 2019
Brentuximab vedotin 50mg powder for concentrate for solution for infusion (Adcetris ®) SMC2098	Treatment of adult patients with CD30+ cutaneous T-cell lymphoma after at least one prior systemic therapy.	Not available as not recommended for use in NHS Scotland	170	Sep 2018
Brentuximab vedotin 50mg powder for concentrate for solution for infusion (Adcetris	Treatment of adult patients with CD30+ Hodgkin lymphoma at increased risk of relapse or progression following autologous stem cell transplant.	Not routinely available as not recommended for use in NHS Scotland	169	July 2018

®) SMC No 2085				
Brentuximab vedotin (Adcetris®) (989/14)	Adult patients with relapsed or refractory CD30+ Hodgkin lymphoma (HL)	HOSPITAL ONLY - Haematology	142	Oct/Nov 2014
Brentuximab vedotin (Adcetris®) (845/12)	Adult patients with relapsed or refractory CD30+ Hodgkin lymphoma (HL)	Not recommended	124	Feb 2013
bimekizumab 160mg solution for injection in pre-filled syringe/ prefilled pen (Bimzelx) SMC2616	"axial spondyloarthritis			
Brexucabtagene autoleucel 0.4 – 2 × 108 cells dispersion for infusion (Tecartus®) SMC2548	Treatment of adult patients 26 years of age and above with relapsed or refractory B-cell precursor acute lymphoblastic leukaemia (ALL).	Not routinely available as local clinical experts do not wish to add the medicine to the formulary at this time or there is a local preference for alternative medicines.	195	December 2023
Brigatinib 30mg, 90mg and 180mg film-coated tablets (Alunbrig®) SMC2314	Indication under review: as monotherapy for the treatment of adult patients with anaplastic lymphoma kinase (ALK)-positive advanced non-small cell lung cancer (NSCLC) previously not treated with an ALK inhibitor. Brigatinib offers an additional treatment choice in the therapeutic class of tyrosine kinase inhibitors for this indication. Medicines within this therapeutic class have been accepted via the orphan process for this indication.	Available in line with national guidance	183	March 2021
Brigatinib 30mg, 90mg and 180mg film-coated tablets (Alunbrig®) SMC2147	As monotherapy for the treatment of adult patients with anaplastic lymphoma kinase (ALK) positive advanced non-small cell lung cancer (NSCLC) previously treated with crizotinib.	Available in line with local guidance for prescribing.	175	Aug 2019
Brimonidine/brimonidine tartrate (Mirvaso®) (1016/14)	Facial erythema of rosacea in adults	Formulary (GPs under the direction of	145	Feb 2015

		secondary care - Dermatology) (Dermatology Specialist List)		
Brimonidine/timolol (Combigan®)	Eye drops	Formulary (Ophthalmology specialist list)	53	2005
Brinzolamide (Simbrinza®) (991/14)	Decrease of elevated intraocular pressure (IOP) in adult patients with open-angle glaucoma or ocular hypertension for whom monotherapy provides insufficient IOP reduction	Formulary - 2nd line choice (GPs may prescribe under direction of Ophthalmology)	143	Nov/Dec 2014
Brinzolamide/timolol (Azarga®) (568/09)	Ocular hypertension and open angle glaucoma	Formulary (Ophthalmology specialist list)	101 92	Dec 10/Jan11 Aug/Sept 2009
Brinzolamide (Azopt®) (546/09)	Ocular hypertension and open angle glaucoma	Formulary (Ophthalmology specialist list)	101 88	Dec 10/Jan11 Apr 2009
Brivaracetam, 10mg, 25mg, 50mg, 75mg, 100mg film-coated tablets; 10mg/mL oral solution; 10mg/mL solution for injection/infusion (Briviact®) SMC2113	Adjunctive therapy in the treatment of partial-onset seizures with or without secondary generalisation in children from 4 years to ≤15 years of age with epilepsy. SMC restriction: for use in patients with refractory epilepsy and treatment should be initiated by physicians who have appropriate experience in the treatment of epilepsy	Available in line with local guidance for prescribing	173	March 2019
Brivaracetam (Briviact®)1160/16	Adjunctive therapy in the treatment of partial onset seizures with or without secondary generalisation in adult and adolescent patients from 16 years of age with epilepsy. Restriction: for use in patients with refractory epilepsy and treatment should be initiated by physicians who have appropriate experience in the treatment of epilepsy.	Available in line with National Guidance	156 157	Sep 2016 Nov 2016

Brodalumab 210mg solution for injection in pre-filled syringe (Kyntheum®) SMC No 1283/17	For the treatment of moderate to severe plaque psoriasis in adult patients who are candidates for systemic therapy. SMC Restriction: for patients who have failed to respond to standard systemic therapies (including ciclosporin, methotrexate and phototherapy), are intolerant to, or have a contra-indication to these treatments.	Available in line with national guidance	166 169	Feb 2018 July 2018
Brolucizumab 120mg/ml solution for injection and solution for injection in pre-filled syringe (Beovu®) SMC2508	In adults for the treatment of visual impairment due to diabetic macular oedema. SMC restriction: treatment of visual impairment due to diabetic macular oedema in adults with best corrected visual acuity 75 Early Treatment Diabetic Retinopathy Study letters or less at baseline. Brolucizumab offers an additional treatment choice in the class of vascular endothelial growth factor inhibitors in this indication.	Not routinely available as local clinical experts do not wish to add the medicine to the formulary at this time or there is a local preference for alternative medicines.	191	Nov 2022
Brolucizumab 120mg/mL solution for injection in pre-filled syringe (Beovu®) SMC2272	In adults for the treatment of neovascular (wet) age-related macular degeneration (AMD). Non-inferiority of brolucizumab versus another anti-vascular endothelial growth factor medicine was demonstrated for mean change in best corrected visual acuity from baseline to week 48 in two phase III studies in patients with neovascular AMD	Not routinely available as local clinical experts do not wish to add the medicine to the formulary at this time	181	November 2020
Bromfenac (Yellox®) (740/11)	Post-operative ocular inflammation	Not recommended	111	Nov 2011
Budesonide 9mg prolonged release tablet (Cortiment®) Ferring Pharmaceuticals Ltd SMC2448	Induction of remission in patients with active microscopic colitis Cortiment® offers a prolonged release formulation of budesonide for this indication. Other oral budesonide formulations are available at lower cost.	Available in line with local guidance for prescribing	188	April 2022
Budesonide 1mg orodispersible tablets (Jorveza®) SMC2158	Treatment of eosinophilic oesophagitis (EoE) in adults (older than 18 years of age). SMC restriction: For patients unsuccessfully treated with proton pump inhibitors. One randomised, double-blind phase III study, demonstrated superiority of budesonide over placebo in inducing clinico-histologic remission in adult patients with EoE, refractory to	Available in line with national guidance	181	November 2020

	treatment with a proton pump inhibitor.			
Budesonide/formoterol, 100 micrograms/6 micrograms and 200 micrograms/6 micrograms inhalation powder (Symbicort® SMART®) SMC No. (1244/17)	The regular treatment of asthma where use of a combination inhaled corticosteroid and a long-acting β2 adrenoceptor agonist is appropriate: patients not adequately controlled with inhaled corticosteroids and "as needed" short-acting β2 adrenoceptor agonists, or patients already adequately controlled on both inhaled corticosteroids and long-acting β2 adrenoceptor agonists. This advice relates to the extension of the license for Symbicort maintenance and reliever therapy (SMART®) to adolescents aged 12 to <18 years.	Available in line with National Guidance Initiation through Hospital respiratory Clinic only	162	Aug 2017
Budesonide/formoterol 200micrograms/6 mcg inhalation powder and 400micrograms/12 inhalation powder (Symbicort Turbohaler®) budesonide/ formoterol 200 micrograms/6 micrograms per actuation, pressurised inhalation, suspension (Symbicort®) SMC 1198/16	In adults for induction of remission in patients with mild to moderate active ulcerative colitis (UC) where aminosalicylate (5-ASA) treatment is not sufficient.	Not available as not recommended for use in NHS Scotland.	158	Dec 2016
Budesonide/formoterol (Symbicort® Turbohaler®) 200 micrograms/6 micrograms/inhalation, inhalation powder SMC2622	For use in patients who would otherwise receive low dose inhaled corticosteroid (ICS) maintenance therapy plus short-acting beta-2 adrenoceptor agonist (SABA) as needed.	Not routinely available as local implementation plans are being developed or the ADTC is waiting for further advice from local clinical experts - decision expected before the end of 2024.	197	May/June 2024
Budesonide 9mg prolonged release tablets (Cortiment®) (1093/15)	For use in adults for induction of remission in patients with mild to moderate active ulcerative colitis (UC) where 5-ASA treatment is not sufficient.	Available in line with national guidance.	152 158	Nov/Dec 2015 Dec 2016

Budesonide (Budenofalk®) (1043/15)	For the treatment for the indication autoimmune hepatitis (AIH).	Non Formulary - absence of clinician demand	148	May 2015
Budesonide 9mg granules (Budenofalk®) (970/14)	Induction of remission in patients with mild to moderate active Crohn's disease.	Formulary (alternative to capsules in patients with swallowing difficulties)	139	June/July 2014
Budesonide 3mg capsule (Budenofalk®) (828/12)	Symptomatic relief of chronic diarrhoea due to collagenous colitis.	GPs may prescribe under the direction of the GI Clinic	124	Feb 2013
Budesonide 9mg granules (Budenofalk®) (831/12)	Induction of remission in patients with active collagenous colitis	GPs may prescribe under the direction of the GI Clinic	124	Feb 2013
Budesonide CFC-free inhaler (Pulmicort®) *Discontinued March 2011	Asthma	Discontinued	88	Apr 2009
Budesonide rectal foam (Budenofalk®) (409/07)	Active ulcerative colitis	Formulary	73	Oct 2007
Budesonide/formoterol (Symbicort Smart®) (362/07)	Asthma maintenance and reliever therapy	Formulary	69 Further info	June 2007
Budesonide/formoterol (Symbicort Turbohaler®)	Severe COPD		100 Further info 39	Oct/Nov 2010 2004
Budesonide inhaler (Easyhaler® Budesonide)	Asthma	Formulary	56	2006
Budesonide inhaler (Novolizer Budesonide®)	Asthma	Non-formulary	61	2006
Bulevirtide 2mg powder for solution for injection (Hepcludex®)	For the treatment of chronic hepatitis delta virus (HDV) infection in plasma (or serum) HDV-RNA positive adult patients with compensated liver disease.	Not routinely available as local clinical experts do not wish to add the medicine to the formulary at this time or there		

		is a local preference for alternative medicines.		
Bupivacaine HCL (Bufyl®) (761/12)	Epidural analgesia to relieve pain during labour and to control post operative pain.	Non-formulary alternatives preferred	116	Apr/May 2012
Buprenorphine/naloxone 1.4mg/0.36mg, 2.9mg/0.71mg, 5.7mg/1.4mg, 8.6mg/2.1mg, 11.4mg/2.9mg sublingual tablets (Zubsolv®) SMC2123	Substitution treatment for opioid drug dependence, within a framework of medical, social and psychological treatment. The intention of the naloxone component is to deter intravenous misuse. Treatment is intended for use in adults and adolescents over 15 years of age who have agreed to be treated for addiction. SMC restriction: for use in patients for whom methadone is not suitable.	Not routinely available as local clinical experts do not wish to add the medicine to the formulary at this time or there is a local preference for alternative medicines.	191	Nov 2022
Buprenorphine 74.2mg implant (Sixmo®) SMC2372	For substitution treatment for opioid dependence in clinically stable adult patients who require no more than 8 mg/day of sublingual buprenorphine, within a framework of medical, social and psychological treatment. Buprenorphine implant was non-inferior to buprenorphine-naloxone sublingual tablets for controlling illicit drug use in patients transferred from stable daily doses of sublingual buprenorphine up to 8mg.	Not routinely available as local clinical experts do not wish to add the medicine to the forulary at this time or there is a local preference for alternative medicines	188	April 2022
Buprenorphine/naloxone 2mg/0.5mg and 8mg/2mg sublingual film (Suboxone®) SMC 2316	Substitution treatment for opioid drug dependence, within a framework of medical, social and psychological treatment. The intention of the naloxone component is to deter intravenous misuse. Buprenorphine/naloxone is indicated in adults and adolescents over 15 years of age who have agreed to be treated for addiction. SMC restriction: to those patients in whom methadone is not suitable and for whom the use of buprenorphine is considered appropriate.	Not routinely available as local clinical experts do not wish to add the medicine to the forulary at this time or there is a local preference for alternative medicines.	183	March 2021

	Buprenorphine/naloxone sublingual film (Suboxone®) and buprenorphine/naloxone sublingual tablets (Suboxone®) deliver similar plasma concentrations of buprenorphine but are not bioequivalent. Please refer to the relevant Summary of Product Characteristics for further detail, including guidance on switching between formulations.			
Buprenorphine/naloxone (Suboxone®) (355/07)	Opioid drug dependence	Not recommended	107 67	July 2011 Mar 2007
Buprenorphine 8/16/24/32/64/96/128 mg prolonged-release solution for injection (Buvidal®) SMC2169	Treatment of opioid dependence within a framework of medical, social and psychological treatment. Treatment is intended for use in adults and adolescents aged 16 years or over. SMC restriction: Use in patients in whom methadone is not suitable and for whom the use of buprenorphine is considered appropriate	Available in line with local guidance for prescribing	176	Oct 2019
Buprenorphine, 2mg, 8mg oral lyophilisate (Espranor®) SMC No (1245/17)	Substitution treatment for opioid drug dependence, within a framework of medical, social and psychological treatment. Treatment with buprenorphine oral lyophilisate is intended for use in adults and adolescents aged 15 years or over who have ag reed to be treated for addiction. Restriction: to patients in whom methadone is not suitable.	Available in line with National guidance Restricted to use in TSMS Formulary - specialist prescribing	162	Aug 2017
Buprenorphine 5, 10, 15 and 20 microgram/hour transdermal patch (Butec®) SMC No. 1213/17	In adults, for the treatment of chronic non-malignant pain of moderate intensity when an opioid is necessary for obtaining adequate analgesia. SMC Restriction: for use in patients over 65 years	Available in line with local guidance for prescribing	159 161	Feb 2017 Jun 2017
Buprenorphine patch (BuTrans®) (234/06)	Severe opioid responsive pain	Not recommended	86 82 68 55	Jan 2009 Aug/Sept 2008 May 2007 2006

Buprenorphine patch (Transtec®)	Moderate to severe pain	Not recommended	44	2004
Burosumab 10mg, 20mg and 30mg solution for injection (Crysvita®) SMC2514	Key points: • X-linked hypophosphataemia is a rare genetic condition. In adults, symptoms include pathological fractures or pseudofractures with impaired healing, early osteoarthritis, dental problems and an increased risk of osteoporosis. These symptoms are associated with pain and stiffness, may limit physical function and impact quality of life. • In a phase III study, burosumab significantly increased the proportion of patients achieving mean serum phosphate above the lower level of normal, compared with placebo over 24 weeks of treatment. There were no meaningful differences between burosumab and placebo for quality of life measurements assessed at week 24. • Only open-label and uncontrolled data (for less than 3 years of treatment) are available to support burosumab benefits in relation to phosphate levels and symptoms in the long term with continuous treatment. There is uncertainty about long-term efficacy and safety of burosumab, a potentially lifelong treatment, and there are no data to support a mortality benefit with burosumab. • The submitting company has positioned burosumab for use in symptomatic adult patients (≥18 years old). There is a lack of data against conventional therapy. Uncertainty remains about the relative effectiveness of burosumab against this relevant comparator. • The cost of burosumab in relation to its health benefits remains high and there are outstanding uncertainties relating	Not routinely available as local clinical experts do not wish to add the medicine to the formulary at this time or there is a local preference for alternative medicines.	192	April 2023

	to clinical and quality of life data used in the model.			
Burosumab 10mg, 20mg, and 30mg solution for injection (Crysvita®) SMC 2240	Treatment of X-linked hypophosphataemia with radiographic evidence of bone disease in children 1 year of age and older and adolescents with growing skeletons.	Available in line with national guidance	179	Apr 2020
Burosumab (Crysvita) SMC2588	For the treatment of X-linked hypophosphataemia in children and adolescents aged 1 to 17 years with radiographic evidence of bone disease	Not routinely available as local clinical experts do not wish to add the medicine to the formulary at this time or there is a local preference for alternative medicines.	196 - Awaiting publication	Feb 2024
Busulfan IV (Busilvex®)	Conditioning treatment prior to conventional haematopoietic progenitor cell transplantation (HPCT) in paediatric and adult patients		65	Jan 2007

Updated: 9th June 2025

Back to top Back to homepage